News

The decrease in the net loss is mainly attributable to a decrease in the accretion in the carrying value of the convertible senior unsecured notes and interest due

Concert Pharmaceuticals, a biotechnology company, has announced positive Phase I clinical trial results of CTP-347, an investigational non-hormonal treatment for vasomotor symptoms or hot flashes. CTP-347, a novel

Daiichi Sankyo Company has announced that it will restructure its subsidiary Asubio Pharma in April 2010 as a drug discovery venture business and be relocated in October 2010

The randomized double-blind, placebo and positive controlled trial involving approximately 120 adult female women began in early March 2009 with data expected in approximately 60 days. In an

In June 2006 Questcor submitted a supplemental new drug application (sNDA) to the FDA and in May 2007 the FDA determined the sNDA was not approvable in the

AR-42 is an orally available, novel, potent, small molecule that modifies the acetylation of histones and other molecules, and is a targeted inhibitor of the Pan-DAC and Akt

Gross profit from continuing operations was $3.4 million or 55% during the fourth quarter of 2008 compared to $3.9 million or 60% during the comparable period of 2007.

According to Lifeline Biotechnologies, OvaScope has been designed and developed to assist in the early detection of ovarian cancer. To date, the preliminary testing has proved to be

Once the abbreviated new drug application (ANDA) is approved by FDA, Global Pharmaceuticals, Impax’s generic division, will commercialize the products. Doryx is a tetracycline-class antibacterial indicated for rickettsial